Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in ER-positive, HER2-positive Breast Cancer (neoPEHP): an Exploratory, Open-label, Multi-center Phase 2 Study

NCT04858516 is registered in ClinicalTrials.gov with Guangdong Provincial People's Hospital as lead sponsor.

NCT NCT04858516
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04858516 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in ER-positive, HER2-positive Breast Cancer (neoPEHP): an Exploratory, Open-label, Multi-center Phase 2 Study
Lead sponsor
Guangdong Provincial People's Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
April 30, 2021
Completion date
April 30, 2025
Enrollment
57 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

neoadjuvant treatment for her2-positive, er-positive breast cancer